



Bangalore, India, October 29, 2010

Press Release

Strides Arcolab receives ANDA approval from USFDA for Lamivudine and Zidovudine under PEPFAR scheme

Total PEPFAR approvals - 16

Strides Arcolab Limited (BSE: 532531, NSE: STAR) today announced that it has received tentative approval from the United States – Food and Drug Administration for one new drug application (ANDA) for fixed dose combination of Lamivudine and Zidovudine Tablets 150 mg / 300 mg under the expedited review provisions of the President's Emergency Plan for AIDS Relief (PEPFAR).

The company supplies ARV products to global procurement agencies and this approval adds to the overall basket of medicines available.

Strides Arcolab Limited: Leadership through Partnering

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables. The Company has 14 manufacturing facilities across 6 countries and has a marketing presence in more than 60 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore. Additional information is available at the Company's website at www.stridesarco.com.

For further information, please contact:

Strides

Ms. Aloka Sengupta – President Business
Development, India Operations
+91 80 66580748

Mr. Kannan. N (Investors)
+91 98450 54745

Melissa Arulappan (Media)
+91 98450 22389

PR Consultancy

Mr. Mahesh Nair, Corporate Voice/Weber
Shandwick
+91 9880376648
mareshn@corvoshandwick.co.in

Ms. Kasturi Wasmatar
+91 9916728393
kasturi@corvoshandwick.co.in

